Inhibrx Biosciences, Inc.
INBX
$111.94
-$0.92-0.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.60% | -1.85% | 6.87% | -23.04% | 33.84% |
| Total Depreciation and Amortization | -2.61% | -4.79% | -3.26% | -11.80% | -2.07% |
| Total Amortization of Deferred Charges | 76.37% | 14.02% | 0.63% | 1.92% | 17.45% |
| Total Other Non-Cash Items | 15.27% | -2.64% | -11.36% | 13.07% | 11.44% |
| Change in Net Operating Assets | 114.51% | -424.20% | 49.90% | 40.98% | -274.49% |
| Cash from Operations | 21.32% | -26.24% | 10.94% | -12.92% | 16.55% |
| Capital Expenditure | -- | -- | 100.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | 100.00% |
| Total Debt Issued | -100.00% | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 240.55% | -62.44% | 256.25% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -97.87% | 5,917.78% | 256.25% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.63% | 229.68% | 13.77% | -11.77% | -146.86% |